Stoke Therapeutics, Inc.
DE ˙ DB ˙ US86150R1077
26,68 € ↑0,13 (0,49%)
2026-05-29
DEL PRIS
SecurityDE:0GT / Stoke Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership150,045 shares
Latest Disclosed Value $ 4,885,466
Invesco Ltd. reports 42.19% decrease in ownership of 0GT / Stoke Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 150,045 shares of Stoke Therapeutics, Inc. (DE:0GT) valued at $4,111,233 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 259,543 shares of Stoke Therapeutics, Inc.. This represents a change in shares of -42.19% during the quarter. The current value of the position is $4,003,201 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F STOKE THERAPEUTICS COM 86150R107 150,045 -109,498 -42.19 4,885 -40.69 0.0007
2026-02-19 2025-12-31 13F STOKE THERAPEUTICS COM 86150R107 259,543 51,468 24.74 8,238 68.48 0.0013
2025-11-13 2025-09-30 13F STOKE THERAPEUTICS COM 86150R107 208,075 167,868 417.51 4,890 972.15 0.0008
2025-08-13 2025-06-30 13F STOKE THERAPEUTICS COM 86150R107 40,207 14,024 53.56 456 162.07 0.0001
2025-05-12 2025-03-31 13F STOKE THERAPEUTICS COM 86150R107 26,183 14,118 117.02 174 30.83 0.0000
2025-02-13 2024-12-31 13F STOKE THERAPEUTICS COM 86150R107 12,065 12,065 133 0.0000
2024-11-12 2024-09-30 13F STOKE THERAPEUTICS COM 86150R107 0 -437,136 -100.00 0 -100.00
2024-08-13 2024-06-30 13F STOKE THERAPEUTICS COM 86150R107 437,136 437,136 5,906 0.0012
2022-08-15 2022-06-30 13F STOKE THERAPEUTICS COM 86150R107 0 -131,674 -100.00 0 -100.00
2022-05-16 2022-03-31 13F STOKE THERAPEUTICS COM 86150R107 131,674 131,674 2,772 0.0007
2022-02-14 2021-12-31 13F STOKE THERAPEUTICS COM 86150R107 0 -9,325 -100.00 0 -100.00
2021-11-15 2021-09-30 13F STOKE THERAPEUTICS COM 86150R107 9,325 1,323 16.53 237 -11.90 0.0001
2021-08-17 2021-06-30 13F STOKE THERAPEUTICS COM 86150R107 8,002 8,002 269 0.0001
2021-05-17 2021-03-31 13F STOKE THERAPEUTICS COM 86150R107 0 -25,329 -100.00 0 -100.00
2021-02-16 2020-12-31 13F STOKE THERAPEUTICS COM 86150R107 25,329 25,329 1,568 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.